Patent Grant
8304405
The present invention relates to pharmaceutical products and formulations. More particularly the present invention relates to pharmaceutical products and formulations useful for preventing or minimising allergic reactions. More particularly, but not exclusively, the present invention relates to pharmaceutical products and formulations for nasal and ocular use.
Such allergic reactions commonly comprise the allergy-related and vasomotor-related symptoms and the rhinovirus-related symptoms.
It is known to use antihistamines in nasal sprays and eye drops to treat allergy-related conditions. Thus, for example, it is known to use the antihistamine azelastine (usually as the hydrochloride salt) as a nasal spray against seasonal or perennial allergic rhinitis, or as eye drops against seasonal and perennial allergic conjunctivitis.
It is also known to treat these conditions using a corticosteroid, which will suppress nasal and ocular inflammatory conditions. Among the corticosteroids known for nasal use are, for example, beclomethasone, mometasone, fluticasone, budesonide and ciclesonide. Corticosteroids known for ocular anti-inflammatory use include betamethasone sodium, dexamethasone sodium and prednisolone acetate, for example.
It would be highly desirable, however, to provide a treatment that combines the effects of anti-histamine treatments and steroid treatments, in a pharmaceutically acceptable formulation, which is tolerated in situ, without significantly disrupting the potency of the constituent pharmaceuticals.
We have now found that, very surprisingly, azelastine (4-[(4-Chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone), or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, preferably in salt form and even more preferably in the form of the hydrochloride salt, can advantageously be combined with a steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, to provide a stable, very effective combination product or formulation preferably for nasal or ocular treatment. The combination can provide, in a single administration or dosing regime, the antihistaminic properties of azelastine and the anti-inflammatory (and/or other) properties of the steroid, without any significant interference between the two, or adverse reaction in situ.
In one aspect the invention provides a pharmaceutical formulation comprising azelastine or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof and a steroid, preferably a corticosteroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof the formulation preferably being in a form suitable for administration nasally or ocularly. In an embodiment, the formulation contains the steroid in an amount from about 50 micrograms/ml to about 5 mg/ml of the formulation. In an embodiment, the formulation contains a suspension containing 0.0005% to 2% (weight/weight of the formulation) of azelastine or a pharmaceutically acceptable salt of azelastine, and from 0.5% to 1.5% (weight/weight of the formulation) of said steroid. In an embodiment, the formulation contains a suspension containing from 0.001% to 1% (weight/weight of the formulation) azelastine, or salt thereof, and from 0.5% to 1.5% (weight/weight of the formulation) steroid.
The term “physiologically functional derivative” as used herein denotes a chemical derivative of any of the specific therapeutic agents described herein having the same or similar physiological function as the free base therapeutic agent and, for example, being convertible in the body thereto. According to the present invention, examples of physiologically functional derivatives include esters.
The preferred forms of formulations of the invention are nasal drops, eye drops, nasal sprays, nasal inhalation solutions or aerosols or insufflation powders.
Preferred embodiments of the invention can comprise stable aqueous solutions of azelastine or one or more of its salts, in combination with steroids which may be beclomethasone, mometasone, fluticasone, budesonide or ciclesonide, which can be used in the form of inhalation solution, pressurized aerosol, eye drops or nasal drops, and in a particular preferred embodiment, in the form of a spray (preferably a nasal spray). The spray can, for example, be formed by the use of a conventional spray-squeeze bottle or a pump vaporizer. In addition, it is also possible to use compressed gas aerosols. In a preferred embodiment, 0.03 to 3 mg of azelastine base and 0.05 to 0.15 mg of the steroid should be released per individual actuation.
The formulations preferably contain a preservative and/or stabilizer. These include, for example: ethylene diamine tetra-acetic acid (edetic acid) and its alkali salts (for example dialkali salts such as disodium salt, calcium salt, calcium-sodium salt), lower alkyl p-hydroxybenzoates, chlorhexidine (for example in the form of the acetate or gluconate) and phenyl mercury borate. Other suitable preservatives are: pharmaceutically useful quaternary ammonium compounds, for example cetylpyridinium chloride, tetradecyltrimethyl ammonium bromide, generally known as “cetrimide”, benzyldimethyl-[2-[2-[p-(1,1,3,3-tetramethyl-butyl)phenoxy]ethoxy]-ammonium chloride, generally known as “benzethonium chloride” and myristyl picolinium chloride. Each of these compounds may be used in a concentration of 0.002 to 0.05%, for example 0.02% (weight/volume in liquid formulations, otherwise weight/weight). Preferred preservatives among the quaternary ammonium compounds are, however, alkylbenzyl dimethyl ammonium chloride and mixtures thereof, for example the compounds generally known as “benzalkonium chloride.”
The total amount of preservatives in the formulations (solutions, ointments, etc.) is preferably from 0.001 to 0.10 g, preferably 0.01 g per 100 ml of solution/suspension or 100 g of formulation.
In the case of preservatives, the following amounts of individual substances can, for example, be used: thimero sal 0.002-0.02%; benzalkonium chloride 0.002 to 0.02% (in combination with thimero sal the amount of thimero sal is, for example=0.002 to 0.005%); chlorhexidine acetate or gluconate 0.01 to 0.02%; phenyl mercuric/nitrate, borate, acetate 0.002-0.004%; p-hydroxybenzoic acid ester (for example, a mixture of the methyl ester and propyl ester in the ratio 7:3): preferably 0.05-0.15, more preferably 0.1%.
The preservative used is preferably a combination of edetic acid (for example, as the disodium salt) and benzalkonium chloride. In this combination, the edetic acid is preferably used in a concentration of 0.05 to 0.1%, benzalkonium chloride preferably being used in a concentration of 0.005 to 0.05%, more preferably 0.01%.
In the case of solutions/suspensions reference is always made to percent by weight/volume, in the case of solid or semi-solid formulations to percent by weight/weight of the formulation.
Further auxiliary substances which may, for example, be used for the formulations of the invention are: polyvinyl pyrrolidone, sorbitan fatty acid esters such as sorbitan trioleate, polyethoxylated sorbitan fatty acid esters (for example polyethoxylated sorbitan trioleate), sorbimacrogol oleate, synthetic amphotensides (tritons), ethylene oxide ethers of octylphenolformaldehyde condensation products, phosphatides such as lecithin, polyethoxylated fats, polyethoxylated oleotriglycerides and polyethoxylated fatty alcohols. In this context, polyethoxylated means that the relevant substances contain polyoxyethylene chains, the degree of polymerisation of which is generally between 2 to 40, in particular between 10 to 20. These substances are preferably used to improve the solubility of the azelastine component.
It is optionally possible to use additional isotonization agents. Isotonization agents which may, for example, be used are: saccharose, glucose, glycerine, sorbitol, 1,2-propylene glycol and NaCl.
The isotonization agents adjust the osmotic pressure of the formulations to the same osmotic pressure as nasal secretion. For this purpose, these substances are in each case to be used in such amount that, for example, in the case of a solution, a reduction in the freezing point of 0.50 to 0.56 degree C. is attained in comparison to pure water.
In Example 1, it is possible to use instead of NaCl per 100 ml of solution, for example: Glucose 1H2O 3.81 g; saccharose 6.35 g; glycerine 2.2 g; 1,2-propylene glycol 1.617 g; sorbitol 3.84 g (in the case of mixtures of these substances correspondingly less may optionally be used).
Moreover, it is possible to add thickening agents to solutions according to the present invention to prevent the solution from flowing out of the nose too quickly and to give the solution a viscosity of about 1.5 to 3, preferably 2 mPa.
Such thickening agents may, for example, be: cellulose derivatives (for example cellulose ether) in which the cellulose-hydroxy groups are partially etherified with lower unsaturated aliphatic alcohols and/or lower unsaturated aliphatic oxyalcohols (for example methyl cellulose, carboxymethyl cellulose, hydroxypropylmethylcellulose), gelatin, polyvinylpyrrolidone, tragacanth, ethoxose (water soluble binding and thickening agents on the basis of ethyl cellulose), alginic acid, polyvinyl alcohol, polyacrylic acid, pectin and equivalent agents. Should these substances contain acid groups, the corresponding physiologically acceptable salts may also be used.
In the event of the use of hydroxypropyl cellulose, 0.1% by weight of the formulation, for example, is used for this purpose.
In the event of the use of Avicel RC 591 or CL 611, microcrystalline cellulose and carboxymethyl cellulose sodium commercially available from FMC BioPolymer, 0.65-3.0% by weight of the formulation, for example, is used for the purpose.
It is also possible to add to the formulations buffer substances such as citric acid/sodium hydrogensulphate borate buffer, phosphates (sodium hydrogenorthophosphate, disodium hydrogenphosphate), trometamol or equivalent conventional buffers in order, for example, to adjust the formulations to a pH value of 3 to 7, preferably 4.5 to 6.5.
The amount of citric acid is, for example, 0.01 to 0.14 g, preferably 0.04 to 0.05 g, the amount of disodium hydrogenphosphate 0.1 to 0.5 g, preferably 0.2 to 0.3 g per 100 ml of solution. The weights given relate in each case to the anhydrous substances.
In the case of solutions and suspensions, the maximum total concentration of active agent and buffer is preferably less than 5%, in particular less than 2% (weight/volume).
For the nasal application, a solution or suspension can preferably be used which is applied as an aerosol, i.e. in the form of a fine dispersion in air or in another conventional carrier gas, for example by means of a conventional pump vaporizer.
Application as a dosage aerosol is, however, also possible. Dosage aerosols are defined as being pressure packings which contain the azelastine or its salts in combination with steroid, in the form of a solution or suspension in a so-called propellant. The propellant may be a pressurized liquid chlorinated, fluorinated hydrocarbon or mixtures of various chlorinated, fluorinated hydrocarbons as well as propane, butane, isobutene or mixtures of these among themselves or with chlorinated, fluorinated hydrocarbons which are gaseous at atmospheric pressure and room temperature. Hydrofluorocarbons (HFCs), such as HFC 134a, and HFC 227a can also be used, and are preferred for environmental reasons. The pressure packing has a dosage or metering valve which, on actuation, releases a defined amount of the solution or suspension of the medicament. The subsequent very sudden vaporization of the propellant tears the solution or suspension of azelastine into the finest droplets or minute particles which can be sprayed in the nose or which are available for inspiration into the nose. Certain plastic applicators may be used to actuate the valve and to convey the sprayed suspension into the nose.
In the case of application as an aerosol, it is also possible to use a conventional adapter.
Particularly preferred embodiments of the present invention are hereinafter described and it will of course be appreciated that any of the previous description of suitable ingredients and formulation characteristics can also be applicable to the following products and formulations as provided by the present invention.
It will be appreciated, therefore, that the present invention further provides a pharmaceutical product comprising (i) azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, provided in an aerosol formulation preferably together with a propellant typically suitable for MDI delivery, and (ii) at least one steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, provided in an aerosol formulation preferably together with a propellant typically suitable for MDI delivery, as a combined preparation for simultaneous, separate or sequential use in the treatment of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated.
The present invention also provides an aerosol formulation preferably suitable for MDI delivery comprising (i) azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and (ii) at least one steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, together with a propellant.
It will also be appreciated from the above, that the respective therapeutic agents of the combined preparation can be administered simultaneously, either in the same or different pharmaceutical formulations, or separately or sequentially. If there is separate or sequential administration, it will also be appreciated that the subsequently administered therapeutic agents should be administered to a patient within a time scale so as to achieve, or more particularly optimise, the above referred to advantageous synergistic therapeutic effect of a combined preparation as present in a pharmaceutical product according to the present invention.
Suitable propellants for use in pharmaceutical products of formulations as provided by the present invention include 1,1,1,2-tetrafluoroethane (HFA 134a) or 1,1,1,2,3,3,3,-heptafluoropropane (HFA 227), or a combination of both, or mono-fluoro trichloromethane and dichloro difluoromethane, in particular 1,1,1,2-tetrafluoroethane (HFA 134a) or 1,1,1,2,3,3,3-heptafluoropropane (HFA 227), with HFA 134a being preferred.
A pharmaceutical aerosol formulation according to the present invention preferably further comprises a polar cosolvent such as C2-6 aliphatic alcohols and polyols, for example ethanol, isopropanol and propylene glycol, with ethanol often being preferred. Preferably, the concentration of the cosolvent is in the range of about 2 to 10% by weight, typically up to about 5%, of the total formulation.
A pharmaceutical aerosol formulation according to the present invention may further comprise one or more surfactants. Such surfactants can be included to stabilise the formulations and for lubrication of a valve system. Some of the most commonly used surfactants in aerosol formulations are oils derived from natural sources, such as corn oil, olive oil, cottonseed oil and sunflower seed oil, and also phospholipids. Suitable surfactants can include lecithin, oleic acid or sorbitan oleate. In an embodiment, the formulation contains from about 50 micrograms to about 1 milligram of surfactant per ml of the formulation.
A further preferred embodiment of the present invention can be where a formulation or product is provided in the form of insufflatable powder, where preferably the maximum particle size of the substance suitably does not exceed 10 μm. Azelastine or its salts and the steroid may be mixed with inert carrier substances or drawn up onto inert carrier substances. Carrier substances which may, for example, be used are: sugars such as glucose, saccharose, lactose and fructose. Also starches or starch derivatives, oligosaccharides such as dextrins, cyclodextrins and their derivatives, polyvinylpyrrolidone, alginic acid, tylose, silicic acid, cellulose, cellulose derivatives (for example cellulose ether), sugar alcohols such as mannitol or sorbitol, calcium carbonate, calcium phosphate, etc.
In one embodiment, the therapeutic agents employed have a particle size of less than about 10 μm, preferably less than 5 μm.
The use of insufflation powders can represent a preferred embodiment of the present invention and there is provided by the present invention a pharmaceutical product comprising (i) azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, provided as an insufflation powder, and (ii) at least one steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, provided as an insufflation powder, as a combined preparation for simultaneous, separate or sequential use in the treatment of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated.
It will be appreciated from the above, that the respective therapeutic agents of the combined preparation can be administered simultaneously, either in the same or different insufflation powder formulations, or separately or sequentially. If there is separate or sequential administration as discussed above, it will also be appreciated that the subsequently administered therapeutic agents should be administered to a patient within a time scale so as to achieve, or more particularly optimise, the above referred to advantageous synergistic therapeutic effect of a combined preparation as present in a pharmaceutical product according to the present invention.
The present invention also provides an insufflation powder formulation comprising (i) azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and (ii) at least one steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, together with a pharmaceutically acceptable carrier or excipient therefor.
Dry insufflation powder formulations as provided by the present invention can be beneficial where it is required that therapeutic agents as employed according to the present invention are retained in the nasal cavity, and systemic side effects can be minimised or eliminated. Furthermore, insufflation powder formulations as employed in the present invention can be beneficial whereby retention of azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, at the nasal mucosa is improved, and the bitter aftertaste associated with liquid antihistamine formulations significantly reduced, whilst also exhibiting the synergistic therapeutic effect associated with the azelastine/steroid combinations provided by the present invention. By providing a dry insufflation powder formulation of azelastine, together with a steroid, having an average particle size of less than about 10 μm, the therapeutic agents can be restricted primarily to the desired target organ, the nasal mucosa.
A dry powder insufflation formulation according to the present invention can be administered by the use of an insufflator, which can produce a finely divided cloud of the dry powder. The insufflator preferably is provided with means to ensure administration of a substantially pre-determined amount of a formulation or product as provided by the present invention. The powder may be used directly with an insufflator which is provided with a bottle or container for the powder, or the powder may be filled into a capsule or cartridge, such as a gelatin capsule, or other single dose device adapted for administration. The insufflator preferably has means to open the capsule or other dose device.
Preferred combinations of therapeutic agents employed in pharmaceutical products and formulations according to the present invention (in particular nasal sprays or drops, aerosol or insufflation products and formulations as described above) comprise any one of the following combinations.
The present invention further provides, therefore, a pharmaceutical product comprising (i) azelastine, or a pharmaceutically acceptable salt thereof, and (ii) at least one steroid selected from the group consisting of beclomethasone, fluticasone, mometasone and pharmaceutically acceptable esters thereof, as a combined preparation for simultaneous, separate or sequential use in the treatment of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated. Suitably the esters can be selected from beclomethasone dipropionate, fluticasone propionate, fluticasone valerate, mometasone furoate and mometasone furoate monohydrate.
The present invention also provides a pharmaceutical formulation comprising (i) azelastine, or a pharmaceutically acceptable salt thereof, and (ii) at least one steroid selected from the group consisting of beclomethasone, fluticasone, mometasone and pharmaceutically acceptable esters thereof, together with a pharmaceutically acceptable carrier or excipient therefor. Suitably the esters can be selected from beclomethasone dipropionate, fluticasone propionate, fluticasone valerate, mometasone furoate and mometasone furoate monohydrate.
In the case of a nasal spray, a particularly preferred formulation as provided by the present invention is a nasal spray comprising azelastine, or a pharmaceutically acceptable salt thereof (preferably azelastine hydrochloride), together with mometasone either as the free base or in ester form, preferably as mometasone furoate.
Specific combinations of therapeutic agents employed in pharmaceutical products and formulations according to the present invention comprise any one of the following combinations:
azelastine hydrochloride and beclomethasone dipropionate;
azelastine hydrochloride and fluticasone propionate;
azelastine hydrochloride and fluticasone valerate;
azelastine hydrochloride and mometasone furoate; and
azelastine hydrochloride and mometasone furoate monohydrate.
There is also provided by the present invention a method for the prophylaxis or treatment in a mammal, such as a human, of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated, which method comprises administration of a therapeutically effective amount of a pharmaceutical product substantially as hereinbefore described, as a combined preparation for simultaneous, separate or sequential use in the treatment of such conditions.
The present invention also provides a method for the prophylaxis or treatment in a mammal, such as a human, of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated, which method comprises administration of a therapeutically effective amount of a pharmaceutical formulation substantially as hereinbefore described.
There is also provided by the present invention for use in the manufacture of a medicament for the prophylaxis or treatment in a mammal, such as a human, of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated, a pharmaceutical product, as a combined preparation for simultaneous, separate or sequential use in the treatment of such conditions.
There is further provided by the present invention, therefore, a process of preparing a pharmaceutical product substantially as hereinbefore described, which process comprises providing as a combined preparation for simultaneous, separate or sequential use in the treatment of conditions for which administration of one or more anti-histamine and/or one or more steroid is indicated: (i) azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and (ii) at least one steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof.
The present invention also provides a process of preparing a pharmaceutical formulation substantially as hereinbefore described, which process comprises admixing a pharmaceutically acceptable carrier or excipient with: (i) azelastine, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof, and (ii) at least one steroid, or a pharmaceutically acceptable salt, solvate or physiologically functional derivative thereof. Preferably pharmaceutical formulations according to the present invention can comprise insufflation powder formulations, nasal sprays, nasal inhalation solutions or aerosols substantially as hereinbefore described.
The present invention is now illustrated by the following Examples, which do not limit the scope of the invention in any way. In Examples where only the ingredients of formulations according to the present invention are listed, these formulations are prepared by techniques well known in the art.
Nasal spray or nasal drops with 0.1% azelastine hydrochloride as active ingredient and steroid 0.1%
Dosage aerosol giving off 0.5 mg of azelastine hydrochloride and 50 micrograms of beclomethasone dipropionate freon solvate per stroke.
About 8.0 kg of a mixture of 70 parts by weight of difluorodichloromethane and 30 parts by weight of 1,2dichlorotetrafluoroethane are cooled to about −55 degree C. in an appropriate cooling vessel. A mixture of 0.086 kg of pre-cooled sorbitantrioleate and 0.8600 kg of pre-cooled trichlorofluoromethane are dissolved with stirring into the mixture at −55 degrees C., 0.0688 kg of micronized azelastine hydrochloride, 0.00688 kg of beclomethasone dipropionate freon solvate and 0.0688 kg of micronized lactose are then incorporated in portions into the solution thereby obtained with intensive stirring. The total weight of the suspension thereby obtained is made up to 9.547 kg through addition of more of the mixture of 70 parts by weight of difluorodichloromethane and 30 parts by weight of 1,2-dichlorotetrafluoroethane cooled to about −55 degree C.
Following closure of the cooling vessel the suspension is again cooled to about −55 degrees C. under intensive stirring. It is then ready to be filled.
Nasal spray or nasal drops with Azelastine and steroid*
*Each spray delivers Azelastine Hydrochloride (140 mcg) and Fluticasone propionate (50 mcg).
Nasal spray or nasal drops with Azelastine and steroid*
*Each spray delivers Azelastine Hydrochloride (140 mcg) and Fluticasone valerate (50 mcg).
Nasal spray or nasal drops with Azelastine and steroid*
*Each spray delivers Azelastine Hydrochloride (140 mcg) and Fluticasone propionate (50 mcg).
Nasal spray or nasal drops with Azelastine and steroid
Nasal spray or nasal drops with Azelastine and steroid*
*Each spray delivers Azelastine Hydrochloride (140 mcg) and Mometasone furoate (50 mcg).
Nasal MDI with Azelastine and steroid
Nasal MDI with Azelastine and steroid
Nasal MDI with Azelastine and steroid
Nasal MDI with Azelastine and steroid
Insufflatable powders containing Azelastine and Steroid:
| Number | Date | Country | Kind |
|---|---|---|---|
| 0213739.6 | Jun 2002 | GB | national |
This is a Divisional Application of U.S. patent application Ser. No. 10/518,016, filed Jul. 6, 2005 and published as US 2006/0025391 A1, now U.S. Pat. No. 8,168,620 and entitled “Combination of Azelastine and Steroids,” which was a filing under 35 U.S.C. 371 of International Application No. PCT/GB03/02557 filed Jun. 13, 2003, entitled “Combination of Azelastine and Steroids,” claiming priority of Great Britain Patent Application No. 0213739.6 filed Jun. 14, 2002, which applications are incorporated by reference herein in their entirety.
| Number | Name | Date | Kind |
|---|---|---|---|
| 2837464 | Nobile | Jun 1958 | A |
| 3067197 | Agnello et al. | Dec 1962 | A |
| 3312590 | Elks et al. | Apr 1967 | A |
| 3506694 | Oxley | Apr 1970 | A |
| 3557162 | Voorschoten et al. | Jan 1971 | A |
| 3639434 | Oxley et al. | Feb 1972 | A |
| 3755302 | Ercoli et al. | Aug 1973 | A |
| 3828080 | May et al. | Aug 1974 | A |
| 3856828 | Phillipps et al. | Dec 1974 | A |
| 3891631 | Phillipps et al. | Jun 1975 | A |
| 3981894 | Phillipps et al. | Sep 1976 | A |
| 3989686 | Phillipps et al. | Nov 1976 | A |
| 4093721 | Phillipps et al. | Jun 1978 | A |
| 4113680 | Kamano et al. | Sep 1978 | A |
| 4187301 | Edwards | Feb 1980 | A |
| 4188385 | Edwards | Feb 1980 | A |
| 4198403 | Alvarez | Apr 1980 | A |
| 4221787 | Bodor et al. | Sep 1980 | A |
| 4261984 | Alvarez | Apr 1981 | A |
| 4263289 | Edwards | Apr 1981 | A |
| 4267173 | Draper | May 1981 | A |
| 4285937 | Kalvoda | Aug 1981 | A |
| 4310466 | Edwards | Jan 1982 | A |
| 4335121 | Phillipps et al. | Jun 1982 | A |
| 4377575 | Stache et al. | Mar 1983 | A |
| 4472393 | Shapiro | Sep 1984 | A |
| 4607028 | Schmidlin | Aug 1986 | A |
| 4710495 | Bodor | Dec 1987 | A |
| 4861765 | Mitsukuchi et al. | Aug 1989 | A |
| 4992474 | Skidmore et al. | Feb 1991 | A |
| 4994439 | Longnecker et al. | Feb 1991 | A |
| 4996335 | Bodor | Feb 1991 | A |
| 5063222 | Komoto et al. | Nov 1991 | A |
| 5081113 | Claussner et al. | Jan 1992 | A |
| 5086050 | Hettche et al. | Feb 1992 | A |
| 5164194 | Hettche | Nov 1992 | A |
| 5202316 | Claussner et al. | Apr 1993 | A |
| 5232919 | Scheffler et al. | Aug 1993 | A |
| 5271946 | Hettche | Dec 1993 | A |
| 5362721 | Stache et al. | Nov 1994 | A |
| 5420120 | Boltralik | May 1995 | A |
| 5608093 | Stache et al. | Mar 1997 | A |
| 5658549 | Akehurst et al. | Aug 1997 | A |
| 5658919 | Ratnaraj et al. | Aug 1997 | A |
| 5707984 | Tjoeng et al. | Jan 1998 | A |
| 5837699 | Sequeira et al. | Nov 1998 | A |
| 5849265 | Li-Bovet et al. | Dec 1998 | A |
| 5889015 | Sequeira et al. | Mar 1999 | A |
| 5914122 | Otterbeck et al. | Jun 1999 | A |
| 5972920 | Seidel | Oct 1999 | A |
| 5981517 | Bodor | Nov 1999 | A |
| 6017963 | Alfonso et al. | Jan 2000 | A |
| 6057307 | Sequeira et al. | May 2000 | A |
| 6127353 | Yuen et al. | Oct 2000 | A |
| 6136294 | Adjei et al. | Oct 2000 | A |
| 6197761 | Biggadike et al. | Mar 2001 | B1 |
| 6261539 | Adjei et al. | Jul 2001 | B1 |
| 6294153 | Modi | Sep 2001 | B1 |
| 6319513 | Dobrozsi | Nov 2001 | B1 |
| 6330938 | Herve et al. | Dec 2001 | B1 |
| 6391340 | Malmqvist-Granlund et al. | May 2002 | B1 |
| 6395300 | Straub et al. | May 2002 | B1 |
| 6416743 | Fassberg et al. | Jul 2002 | B1 |
| 6525228 | Chauvin et al. | Feb 2003 | B2 |
| 6537983 | Biggadike et al. | Mar 2003 | B1 |
| 6583180 | Link et al. | Jun 2003 | B2 |
| 6787532 | Biggadike et al. | Sep 2004 | B2 |
| 6921757 | Cuenoud et al. | Jul 2005 | B2 |
| 7101866 | Biggadike et al. | Sep 2006 | B2 |
| 7244742 | Pieper et al. | Jul 2007 | B2 |
| 7776315 | Pairet et al. | Aug 2010 | B2 |
| 20020061281 | Osbakken et al. | May 2002 | A1 |
| 20020076382 | Kaplan et al. | Jun 2002 | A1 |
| 20020081266 | Woolfe et al. | Jun 2002 | A1 |
| 20020103392 | Stache et al. | Aug 2002 | A1 |
| 20020165211 | Biggadike et al. | Nov 2002 | A1 |
| 20020173496 | Biggadike | Nov 2002 | A1 |
| 20020177581 | Biggadike | Nov 2002 | A1 |
| 20030018019 | Meade et al. | Jan 2003 | A1 |
| 20030073676 | Biggadike et al. | Apr 2003 | A1 |
| 20030109511 | Biggadike et al. | Jun 2003 | A1 |
| 20030144257 | Biggadike et al. | Jul 2003 | A1 |
| 20030158163 | Cuenoud et al. | Aug 2003 | A1 |
| 20040053904 | Komoto et al. | Mar 2004 | A1 |
| 20040136918 | Garrett et al. | Jul 2004 | A1 |
| 20040204399 | Osbakken et al. | Oct 2004 | A1 |
| 20040235807 | Weinrich et al. | Nov 2004 | A1 |
| 20040242638 | Yanni et al. | Dec 2004 | A1 |
| 20050163724 | Miyadia et al. | Jul 2005 | A1 |
| 20050192261 | Jost-Price et al. | Sep 2005 | A1 |
| 20060025391 | Lulla et al. | Feb 2006 | A1 |
| 20060110331 | Dang et al. | May 2006 | A1 |
| 20060228306 | Lane | Oct 2006 | A1 |
| 20070020330 | Dang et al. | Jan 2007 | A1 |
| 20090286762 | Myles et al. | Nov 2009 | A1 |
| 20100152147 | Fuge et al. | Jun 2010 | A1 |
| Number | Date | Country |
|---|---|---|
| 2003244799 | Dec 2003 | AU |
| 889563 | Nov 1981 | BE |
| 1059906 | Jun 1959 | DE |
| 2164058 | Jul 1972 | DE |
| 3836579 | May 1989 | DE |
| 19947234 | Sep 1999 | DE |
| 10152369 | May 2002 | DE |
| 0004773 | Oct 1979 | EP |
| 0057401 | Aug 1982 | EP |
| 0179583 | Apr 1986 | EP |
| 0393658 | Oct 1990 | EP |
| 0416951 | Mar 1991 | EP |
| 0780127 | Jun 1997 | EP |
| 0780127 | Jun 1997 | EP |
| 1519731 | Apr 2009 | EP |
| 2072051 | Jun 2009 | EP |
| 1191965 | May 1970 | GB |
| 1296458 | Nov 1972 | GB |
| 1384372 | Feb 1975 | GB |
| 1438940 | Jun 1976 | GB |
| 1517278 | Jul 1978 | GB |
| 2079755 | Jan 1982 | GB |
| 2088877 | Jun 1982 | GB |
| 2140800 | Dec 1984 | GB |
| 2389530 | Dec 2003 | GB |
| 109656 | Feb 1998 | IL |
| 04208267 | Jul 1992 | JP |
| 8291072 | Nov 1996 | JP |
| 8291073 | Nov 1996 | JP |
| 2002-053485 | Feb 2002 | JP |
| 8504589 | Oct 1985 | WO |
| 8903390 | Apr 1989 | WO |
| 9015816 | Dec 1990 | WO |
| 9104252 | Apr 1991 | WO |
| 9214472 | Sep 1992 | WO |
| 9531964 | Nov 1995 | WO |
| 9619199 | Jun 1996 | WO |
| 9632151 | Oct 1996 | WO |
| 9701337 | Jan 1997 | WO |
| 9705136 | Feb 1997 | WO |
| 9715298 | May 1997 | WO |
| 9721721 | Jun 1997 | WO |
| 9721724 | Jun 1997 | WO |
| 9724365 | Jul 1997 | WO |
| 9740836 | Nov 1997 | WO |
| 9746243 | Dec 1997 | WO |
| 9817676 | Apr 1998 | WO |
| 9834596 | Aug 1998 | WO |
| 9848839 | Nov 1998 | WO |
| 9901467 | Jan 1999 | WO |
| 9925359 | May 1999 | WO |
| 9932089 | Jul 1999 | WO |
| 0016814 | Mar 2000 | WO |
| 0033892 | Jun 2000 | WO |
| 0038811 | Jul 2000 | WO |
| 0048587 | Aug 2000 | WO |
| 0049993 | Aug 2000 | WO |
| 0066522 | Nov 2000 | WO |
| 0104118 | Jan 2001 | WO |
| 0120331 | Mar 2001 | WO |
| 0154481 | Aug 2001 | WO |
| 0154664 | Aug 2001 | WO |
| 0157025 | Aug 2001 | WO |
| 0162722 | Aug 2001 | WO |
| 0178736 | Oct 2001 | WO |
| 0178739 | Oct 2001 | WO |
| 0178741 | Oct 2001 | WO |
| 0178745 | Oct 2001 | WO |
| 0200199 | Jan 2002 | WO |
| 0200679 | Jan 2002 | WO |
| 0202565 | Jan 2002 | WO |
| 0207767 | Jan 2002 | WO |
| 0208243 | Jan 2002 | WO |
| 0211711 | Feb 2002 | WO |
| 0212265 | Feb 2002 | WO |
| 0212266 | Feb 2002 | WO |
| 0213868 | Feb 2002 | WO |
| 0226723 | Apr 2002 | WO |
| 0236106 | May 2002 | WO |
| 02051422 | Jul 2002 | WO |
| 02053186 | Jul 2002 | WO |
| 02066422 | Aug 2002 | WO |
| 02070490 | Sep 2002 | WO |
| 02076933 | Oct 2002 | WO |
| 02085296 | Oct 2002 | WO |
| 02088167 | Nov 2002 | WO |
| 02100879 | Dec 2002 | WO |
| 03000241 | Jan 2003 | WO |
| 03013427 | Feb 2003 | WO |
| 03033000 | Apr 2003 | WO |
| 03035668 | May 2003 | WO |
| 03040691 | May 2003 | WO |
| 03042229 | May 2003 | WO |
| 03042230 | May 2003 | WO |
| 03048181 | Jun 2003 | WO |
| 03062259 | Jul 2003 | WO |
| 03064445 | Aug 2003 | WO |
| 03066033 | Aug 2003 | WO |
| 03066036 | Aug 2003 | WO |
| 03066656 | Aug 2003 | WO |
| 03072592 | Sep 2003 | WO |
| 03086399 | Oct 2003 | WO |
| 03105856 | Dec 2003 | WO |
| 2004013156 | Feb 2004 | WO |
| 2004019955 | Mar 2004 | WO |
| 2008012338 | Jan 2008 | WO |
| 872389 | Apr 1987 | ZA |
| Number | Date | Country | |
|---|---|---|---|
| 20090318397 A1 | Dec 2009 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 10518016 | US | |
| Child | 12508393 | US |
